High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Schunk, Mirjam ^a   Kumma, Wondimagegn P ^b   Miranda, Isabel Barreto ^a   Osman, Maha E ^c,d   Roewer, Susanne ^d   Alano, Abraham ^b   Löscher, Thomas ^a   Bienzle, Ulrich ^d   Mockenhaupt, Frank P ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Debub University   (Ethiopia)

^c UNIVERSITY OF KHARTOUM   (Sudan)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; ANTIMALARIAL AGENT; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; ETHIOPIA; FEMALE; GENE MUTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MIDDLE AGED; MUTATION; PARASITOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; ETHIOPIA; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; MUTATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREVALENCE; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE;

EID: 33746544131     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-54     Document Type: Article

References (28)

1. Abeku TA, van Oortmarssen GJ, Borsboom G, de Vlas SJ, Habbema J: Spatial and temporal variations of malaria epidemic risk in Ethiopia: factors involved and implications. Acta Trop 2003, 87:331-340.
2. RBM Baseline survey in selected districts in Ethiopia. Report 2001. Ministry of Health, Addis Ababa, Ethiopia.
3. Das P: Ethiopia faces severe malaria epidemic. Lancet 2003, 362:2071.
4. Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O: Efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 2005, 82:391-395.
5. Assessment of the therapeutic efficacy of antimalarial drugs in Ethiopia. Ministry of Health, Addis Ababa, Ethiopia.
6. Derressa W, Ali A, Enqusellassie F: Self-treatment of malaria in rural communities, Butajira, southern Ethiopia. Bull World Health Organ 2003, 81:261-268.
7. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquin resistance. Mol Cell 2000, 6:861-871.
8. Sanchez C, Lanzer M: Changing ideas on chloroquine in Plasmodium falciparum. Curr Opin Infect Dis 2000, 13:653-658.
9. Wernsdorfer WH, Noedl H: Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis 2003, 16:553-558.
10. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380-388.
11. Mockenhaupt FP, Bousema TJ, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, Otchwemah RN, Sauerwein RW, Bienzle U: Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health 2005, 10:901-908.
12. Young MD, Burgess RW: Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ 1959, 20:27-36.
13. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G: Association of genetic mutations in P. vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother 2001, 45:3122-3127.
14. Imwong M, Pukrittakayamee S, Rénia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G: Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 2003, 47:1514-1521.
15. Kippie T: Five Thousand Years of Sustainability? A case study on Gedeo land use. Treemail Publisher, Heelsum, Netherlands; 2002.
16. Malaria Diagnosis and Treatment Guidelines for Health Workers in Ethiopia. Ministry of Health, Addis Ababa, Ethiopia.
17. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN: High sensitivity of detection of human parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol 1993, 61:315-320.
18. Duraisingh MT, Curtis J, Warhurst DC: Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 1998, 89:1-8.
19. Flueck TP, Jelinek T, Kilian AH, Adagu IS, Kabagambe G, Sonnenburg F, Warhurst DC: Correlation of the in vivo-resistance to chloroquine and allelic polymorphisms in Plasmodium falciparum isolates from Uganda. Trop Med Int Health 2000, 5:174-178.
20. Djimde A, Doumbo O, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquin-resistant falciparum malaria. N Engl J Med 2001, 344:257-263.
21. Kebede F, Taffa N, Tedla T: An in-vivo study of falciparum malaria sensitivity to chloroquine in unstable malaria endemic area of central Ethiopia. Ethiop Med J 1999, 37:97-109.
22. Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O: Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 2005, 82:397-390.
23. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM: Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthetase of Kenyan parasites. Antimicrob Agents Chemother 2000, 44:991-996.
24. Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JF: Molecular surveillance of mutations in DHFR and DHPS genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg 2005, 73:1131-1134.
25. Bwijo B, Kaneko A, Takechi M, Zungu LL, Moriyama Y, Lum JK, Tsukahara T, Mita T, Takahashi N, Bergqvist Y, Bjorkman A, Kobayakawa T: High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop 2003, 85:363-373.
26. Mockenhaupt FP, Ehrhardt S, Eggelte TA, Agana-Nsiire P, Stollberg K, Mathieu A, Markert M, Otchwemah RN, Bienzle U: Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. Ann Trop Med Parasitol 2005, 99:723-732.
27. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV: Re-emergence of chloroquine sensitive Plasmodium falciparum Malaria after the cessation of chloroquine use in Malawi. J Infect Dis 2003, 187:1870-1875.
28. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003, 68:413-415.